Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olipudase Alfa in Pediatric ASMD
NCT02292654Phase 2Completed
- Sponsor
- Sanofi
- Start
- May 2015
- Primary completion
- Dec 2019
- Modality
- Replacement Enzymes
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of olipudase alfa in acid sphingomyelinase deficiency (ASMD), sponsored by Sanofi. Primary endpoints: Treatment-Emergent Adverse Events at 64 weeks, Infusion-Associated Reactions at 64 weeks and 14 more. Started May 2015; status: completed.
02
Drugs
olipudase alfa
03
Conditions
acid sphingomyelinase deficiency (ASMD)
Beyond the preview
Go deeper on NCT02292654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02292654.